Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$108M Buy
300,007
+147,785
+97% +$50.6M 0.04% 592
2026
Q1
$53.6M Sell
152,222
-66,305
-30% -$23.6M 0.02% 706
2025
Q4
$71.5M Buy
218,527
+12,743
+6% +$4.04M 0.04% 562
2025
Q3
$57.2M Sell
205,784
-63,476
-24% -$18.4M 0.04% 566
2025
Q2
$75M Buy
269,260
+177,767
+194% +$50.4M 0.06% 434
2025
Q1
$28.3M Buy
91,493
+46,417
+103% +$13.7M 0.03% 613
2024
Q4
$11.7M Sell
45,076
-75,667
-63% -$22.4M 0.02% 786
2024
Q3
$38.8M Buy
120,743
+47,619
+65% +$15.6M 0.05% 442
2024
Q2
$22.8M Sell
73,124
-184,448
-72% -$54.2M 0.04% 532
2024
Q1
$73.2M Sell
257,572
-684,325
-73% -$200M 0.12% 196
2023
Q4
$271M Buy
941,897
+144,153
+18% +$39.3M 0.51% 28
2023
Q3
$214M Buy
797,744
+87,760
+12% +$21.9M 0.44% 41
2023
Q2
$158M Buy
709,984
+63,736
+10% +$14.8M 0.33% 61
2023
Q1
$156M Buy
646,248
+39,731
+7% +$9.75M 0.34% 57
2022
Q4
$159M Sell
606,517
-18,991
-3% -$5.09M 0.36% 50
2022
Q3
$141M Buy
625,508
+58,049
+10% +$14.1M 0.34% 53
2022
Q2
$137M Sell
567,459
-165,312
-23% -$40.5M 0.31% 65
2022
Q1
$177M Sell
732,771
-154,224
-17% -$35.4M 0.34% 53
2021
Q4
$200M Sell
886,995
-297,260
-25% -$62.7M 0.36% 56
2021
Q3
$252M Sell
1,184,255
-18,128
-2% -$4.17M 0.47% 32
2021
Q2
$291M Buy
1,202,383
+72,616
+6% +$17.9M 0.5% 29
2021
Q1
$281M Buy
1,129,767
+70,114
+7% +$16.7M 0.46% 41
2020
Q4
$240M Sell
1,059,653
-139,105
-12% -$32.1M 0.42% 47
2020
Q3
$300M Sell
1,198,758
-182,304
-13% -$45.2M 0.51% 33
2020
Q2
$321M Sell
1,381,062
-367,555
-21% -$83.9M 0.52% 31
2020
Q1
$351M Buy
1,748,617
+368,603
+27% +$80.5M 0.59% 29
2019
Q4
$331M Buy
1,380,014
+182,509
+15% +$40.2M 0.38% 64
2019
Q3
$232M Sell
1,197,505
-496,897
-29% -$95.4M 0.27% 96
2019
Q2
$312M Sell
1,694,402
-1,068,591
-39% -$191M 0.35% 73
2019
Q1
$525M Sell
2,762,993
-322,075
-10% -$61.5M 0.56% 27
2018
Q4
$601M Buy
3,085,068
+177,493
+6% +$34.6M 0.7% 24
2018
Q3
$603M Buy
2,907,575
+773,506
+36% +$152M 0.58% 35
2018
Q2
$394M Sell
2,134,069
-764,378
-26% -$135M 0.4% 59
2018
Q1
$494M Sell
2,898,447
-743,483
-20% -$136M 0.53% 36
2017
Q4
$633M Buy
3,641,930
+714,906
+24% +$127M 0.66% 25
2017
Q3
$546M Buy
2,927,024
+1,389,028
+90% +$246M 0.65% 23
2017
Q2
$265M Buy
1,537,996
+94,867
+7% +$15.4M 0.35% 69
2017
Q1
$237M Buy
1,443,129
+392,538
+37% +$65.2M 0.31% 75
2016
Q4
$154M Buy
1,050,591
+69,264
+7% +$10.4M 0.21% 125
2016
Q3
$164M Buy
981,327
+28,188
+3% +$4.77M 0.25% 91
2016
Q2
$145M Sell
953,139
-319,484
-25% -$49.7M 0.26% 98
2016
Q1
$191M Sell
1,272,623
-769,121
-38% -$114M 0.34% 63
2015
Q4
$331M Sell
2,041,744
-692,683
-25% -$109M 0.58% 23
2015
Q3
$378M Buy
2,734,427
+170,823
+7% +$26.9M 0.76% 13
2015
Q2
$394M Buy
2,563,604
+751,701
+41% +$120M 0.78% 13
2015
Q1
$290M Buy
1,811,903
+884,162
+95% +$139M 0.66% 24
2014
Q4
$148M Buy
927,741
+489,761
+112% +$76.3M 0.31% 81
2014
Q3
$61.5M Sell
437,980
-219,816
-33% -$28.7M 0.17% 158
2014
Q2
$77.9M Sell
657,796
-260,220
-28% -$30.1M 0.21% 131
2014
Q1
$113M Sell
918,016
-561,856
-38% -$68.1M 0.34% 58
2013
Q4
$169M Sell
1,479,872
-144,473
-9% -$16.4M 0.5% 28
2013
Q3
$182M Sell
1,624,345
-398,185
-20% -$43.2M 0.64% 12
2013
Q2
$200M Buy
+2,022,530
New +$210M 0.71% 9

Other funds holding AMGN

Cliff Asness's AMGN Position: Q2 2026 in Review

Cliff Asness increased its Amgen (AMGN) stake by 97% in Q2 2026, buying an estimated $50.6M and bringing the position to 300,007 shares worth $108M. The position accounts for 0.04% of the portfolio, ranked #592.

Cliff Asness first reported a position in AMGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $633M in Q4 2017. 3,137 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Cliff Asness held 300,007 shares of Amgen worth $108M as of Q2 2026.
  • Cliff Asness bought 147,785 Amgen shares in Q2 2026, an estimated $50.6M.
  • Amgen made up 0.04% of Cliff Asness's portfolio in Q2 2026, its #592 holding.
  • Cliff Asness first reported a position in Amgen in Q2 2013 and has held it in 53 quarters since.
  • Cliff Asness's Amgen position peaked at $633M in Q4 2017.
  • 3,137 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.